Servier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder
All the news from Servier Group
World Leukemia Day: A global initiative to promote diagnosis
Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide
Chronic venous disease: a complex condition with inconsistent treatment
Across the globe, Servier is taking action to promote therapeutic adherence
Servier and BC Partners enter exclusive negotiations for the sale of Biogaran
Seedpods Day: A day of innovative science driven by young researchers
Rethinking talent attraction: a key challenge in a rapidly evolving sector
Boostcamp Patients: at the heart of the innovation process in oncology